TUCSON, Ariz. (KVOA) - Homeland Security Investigations (HSI) agents served a search warrant at a westside Tucson trucking business on Wednesday morning. More than a dozen HSI agents were at Noemi ...
Vor Biopharma (VOR) has jumped onto investors’ radar after strong Phase 3 data for telitacicept in IgA nephropathy, paired with upbeat new Wall Street coverage that frames the drug’s long term ...
Hosted on MSN
Vor Biopharma approves stock option repricing plan
Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Investing.com - JPMorgan initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a $43.00 price target, citing the potential of its telitacicept drug. The target ...
More than 100 Texas higher education institutions can no longer count on future funding opportunities tied to Hispanic students, who make up almost half of the state’s undergraduate population — and ...
Vor Biopharma Inc. (VOR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...
The hardware/software interface (HSI) is where system-on-chip (SoC) software defines the connections between the software and the underlying hardware. Maintaining a precise, synchronized HSI across ...
(RTTNews) - Vor Biopharma Inc. (VOR) announced the pricing of an underwritten public offering of 10 million shares of its common stock at a public offering price of $10.00 per share. The company ...
A physics teacher is suing the school board of Valley Stream Central High School District, alleging a board trustee used her position to influence district officials to remove him from a science ...
Shares of Vor Bio (Nasdaq: NASDAQ:VOR) rose after it reported that its partner, RemeGen (OTCPK:REGMF), met the main goal in a late-stage trial in China evaluating telitacicept for treating Sjögren’s ...
Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. VOR's telitacicept targets multi-billion dollar autoimmune markets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback